- Home
- HMST vs ANNX Comparison
HMST vs ANNX Comparison
Compare HMST & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- ANNX
- Stock Information
- Founded
- HMST 1921
- ANNX 2011
- Country
- HMST United States
- ANNX United States
- Employees
- HMST N/A
- ANNX N/A
- Industry
- HMST Major Banks
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- HMST Finance
- ANNX Health Care
- Exchange
- HMST Nasdaq
- ANNX Nasdaq
- Market Cap
- HMST 263.0M
- ANNX 253.8M
- IPO Year
- HMST 2012
- ANNX 2020
- Fundamental
- Price
- HMST N/A
- ANNX $2.42
- Analyst Decision
- HMST Hold
- ANNX Strong Buy
- Analyst Count
- HMST 3
- ANNX 5
- Target Price
- HMST $14.17
- ANNX $13.00
- AVG Volume (30 Days)
- HMST 148.5K
- ANNX 1.8M
- Earning Date
- HMST 10-28-2025
- ANNX 11-13-2025
- Dividend Yield
- HMST N/A
- ANNX N/A
- EPS Growth
- HMST N/A
- ANNX N/A
- EPS
- HMST N/A
- ANNX N/A
- Revenue
- HMST $78,496,000.00
- ANNX N/A
- Revenue This Year
- HMST $157.89
- ANNX N/A
- Revenue Next Year
- HMST $8.65
- ANNX N/A
- P/E Ratio
- HMST N/A
- ANNX N/A
- Revenue Growth
- HMST N/A
- ANNX N/A
- 52 Week Low
- HMST $8.41
- ANNX $1.29
- 52 Week High
- HMST $16.10
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- HMST 8.91
- ANNX 56.00
- Support Level
- HMST $13.54
- ANNX $2.03
- Resistance Level
- HMST $14.58
- ANNX $2.70
- Average True Range (ATR)
- HMST 0.29
- ANNX 0.15
- MACD
- HMST -1.30
- ANNX 0.05
- Stochastic Oscillator
- HMST 0.00
- ANNX 58.38
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.